• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2020 年 12 月至 2021 年 10 月期间芬兰医护人员中 COVID-19 疫苗有效性的队列研究。

Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.

机构信息

Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.

Population Health Unit, Department of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), Tampere, Finland.

出版信息

Vaccine. 2022 Jan 31;40(5):701-705. doi: 10.1016/j.vaccine.2021.12.032. Epub 2021 Dec 18.

DOI:10.1016/j.vaccine.2021.12.032
PMID:34953607
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8683266/
Abstract

Recently, Covid-19 vaccine effectiveness has decreased especially against mild disease due to emergence of the Delta variant and waning protection. In this register-based study among healthcare workers in Finland, the vaccine effectiveness of two-dose mRNA vaccine series against SARS-CoV-2 infection decreased from 82% (95% CI 79-85%) 14-90 days after vaccination to 53% (43-62%) after 6 months. Similar trend was observed for other series. Waning was not observed against Covid-19 hospitalization. These results facilitate decision-making of booster doses for healthcare workers.

摘要

最近，由于 Delta 变异株的出现和保护效力的下降，Covid-19 疫苗的有效性，尤其是针对轻症疾病的有效性已经下降。在这项针对芬兰医护人员的基于登记的研究中，两剂 mRNA 疫苗系列对 SARS-CoV-2 感染的疫苗效力在接种后 14-90 天从 82%（95%CI 79-85%）下降到 6 个月后的 53%（43-62%）。其他系列也观察到了类似的趋势。对于 Covid-19 住院治疗，没有观察到疫苗效力下降的情况。这些结果为医护人员接种加强针的决策提供了依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9b3/8683266/65a4c1fb7257/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9b3/8683266/fa7704e74140/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9b3/8683266/a70abc7e6b35/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9b3/8683266/65a4c1fb7257/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9b3/8683266/fa7704e74140/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9b3/8683266/a70abc7e6b35/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9b3/8683266/65a4c1fb7257/gr3_lrg.jpg

相似文献

1
Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021.2020 年 12 月至 2021 年 10 月期间芬兰医护人员中 COVID-19 疫苗有效性的队列研究。
Vaccine. 2022 Jan 31;40(5):701-705. doi: 10.1016/j.vaccine.2021.12.032. Epub 2021 Dec 18.
2
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.mRNA 疫苗加强剂对卡塔尔奥密克戎感染的保护效果。
N Engl J Med. 2022 May 12;386(19):1804-1816. doi: 10.1056/NEJMoa2200797. Epub 2022 Mar 9.
3
Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.第三剂 BNT162b2 mRNA 疫苗和既往感染对德尔塔和奥密克戎变异株流行期间预防 SARS-CoV-2 感染的有效性：英国 SIREN 队列研究，2021 年 9 月至 2022 年 2 月。
J Infect. 2024 Jan;88(1):30-40. doi: 10.1016/j.jinf.2023.10.022. Epub 2023 Nov 4.
4
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性：一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
5
Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.mRNA 加强针在西班牙巴伦西亚医护人员中预防 SARS-CoV-2 及其主要变异株感染和住院的效果随时间的变化。
Vaccine. 2024 Jul 25;42(19):4011-4021. doi: 10.1016/j.vaccine.2024.05.011. Epub 2024 May 17.
6
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
7
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.在意大利德尔塔变异株流行期间，mRNA 疫苗对 SARS-CoV-2 感染和重症 COVID-19 的有效性及其保护作用的衰减：回顾性队列研究。
BMJ. 2022 Feb 10;376:e069052. doi: 10.1136/bmj-2021-069052.
8
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).新型冠状病毒病 19（COVID-19）疫苗对日本德尔塔主导和奥密克戎主导期间有症状的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的有效性：一项多中心前瞻性病例对照研究（与 SARS-CoV-2 感染相关的因素和 COVID-19 疫苗的有效性研究）。
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635.
9
The Waning of BNT162b2 Vaccine Effectiveness for SARS-CoV-2 Infection Prevention over Time: A Test-Negative Study in Health Care Professionals of a Health Department from January 2021 to December 2021.随着时间的推移，BNT162b2 疫苗预防 SARS-CoV-2 感染的效力逐渐减弱：2021 年 1 月至 2021 年 12 月期间，一个卫生部门的医疗保健专业人员的阴性检测研究。
Int J Environ Res Public Health. 2022 Oct 25;19(21):13884. doi: 10.3390/ijerph192113884.
10
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.mRNA 疫苗对 COVID-19 相关急诊科和紧急护理就诊以及成人住院的 2 剂和 3 剂效力下降在德尔塔和奥密克戎变异主导期间 - VISION 网络，10 个州，2021 年 8 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263. doi: 10.15585/mmwr.mm7107e2.

引用本文的文献

1
Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.ChAdOx1 nCoV-19（Vaxzevria）初级系列疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）贝塔和德尔塔变异株的有效性：一项全国性研究。
BMC Infect Dis. 2025 Aug 17;25(1):1028. doi: 10.1186/s12879-025-11410-7.
2
Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection.新冠疫苗中和抗体反应和保护作用的比较持续时间以及保护相关因素。
Nat Commun. 2025 May 22;16(1):4748. doi: 10.1038/s41467-025-60024-9.
3
Quantifying the direct and indirect components of COVID-19 vaccine effectiveness during the Delta variant era.

本文引用的文献

1
Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study.接种 SARS-CoV-2 疫苗对芬兰老年人群和慢性病患者感染新冠病毒和住院的效果：一项全国性队列研究的中期分析。
PLoS One. 2021 Nov 18;16(11):e0258704. doi: 10.1371/journal.pone.0258704. eCollection 2021.
2
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021.2021 年 8 月至 9 月，在德尔塔变异株（B.1.617.2）占主导地位期间，疫苗对向家庭接触者传播 SARS-CoV-2 的有效性，荷兰。
Euro Surveill. 2021 Nov;26(44). doi: 10.2807/1560-7917.ES.2021.26.44.2100977.
3
量化德尔塔变异株时期新冠病毒疫苗有效性的直接和间接组成部分。
Epidemiol Infect. 2025 Mar 24;153:e59. doi: 10.1017/S0950268825000354.
4
How do large-scale population studies inform vaccine evaluations in England?大规模人口研究如何为英国的疫苗评估提供信息？
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf006.
5
Effectiveness of the AZD1222 vaccine against COVID-19 hospitalization in Europe: final results from the COVIDRIVE test-negative case-control study.AZD1222疫苗在欧洲预防新冠病毒肺炎住院治疗的有效性：COVIDRIVE检测阴性病例对照研究的最终结果
Eur J Public Health. 2025 Apr 1;35(2):373-378. doi: 10.1093/eurpub/ckae219.
6
Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China.比较吸入式Ad5-nCoV疫苗异源加强针与混合免疫对奥密克戎BA.5感染的保护作用：一项针对中国医院工作人员的队列研究。
BMC Infect Dis. 2024 Dec 18;24(1):1401. doi: 10.1186/s12879-024-10250-1.
7
COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.新冠病毒疫苗对医护人员预防有症状感染和严重感染有效：一项临床综述。
Vaccine X. 2024 Aug 5;20:100546. doi: 10.1016/j.jvacx.2024.100546. eCollection 2024 Oct.
8
A prospective cohort study of SARS-CoV-2 infection-induced seroconversion and disease incidence in German healthcare workers before and during the rollout of COVID-19 vaccines.一项在德国卫生保健工作者中开展的前瞻性队列研究，旨在调查 COVID-19 疫苗接种前和接种期间 SARS-CoV-2 感染诱导的血清转换和疾病发病率。
PLoS One. 2024 Jan 30;19(1):e0294025. doi: 10.1371/journal.pone.0294025. eCollection 2024.
9
Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review.辉瑞/生物技术、莫德纳和阿斯利康疫苗对 SARS-CoV-2 的疫苗效力：系统评价。
Front Public Health. 2023 Oct 24;11:1229716. doi: 10.3389/fpubh.2023.1229716. eCollection 2023.
10
Risk of COVID-19 in different groups of healthcare professionals between February 2020 and June 2021 in Finland: a register-based cohort study.2020年2月至2021年6月芬兰不同医护人员群体中感染新冠病毒的风险：一项基于登记册的队列研究。
Infect Prev Pract. 2023 Jul 6;5(3):100297. doi: 10.1016/j.infpip.2023.100297. eCollection 2023 Sep.
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
4
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.异源ChAdOx1 nCoV-19和mRNA序贯接种疫苗对瑞典有症状新冠病毒感染的有效性：一项全国性队列研究
Lancet Reg Health Eur. 2021 Dec;11:100249. doi: 10.1016/j.lanepe.2021.100249. Epub 2021 Oct 18.
5
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.德尔塔变异株对英国新冠病毒载量及针对新型严重急性呼吸综合征冠状病毒2感染的疫苗效力的影响。
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
6
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.mRNA 新冠病毒疫苗在美国医护人员中的有效性。
N Engl J Med. 2021 Dec 16;385(25):e90. doi: 10.1056/NEJMoa2106599. Epub 2021 Sep 22.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.辉瑞-BioNTech 信使核糖核酸新冠病毒疫苗 6 个月的安全性和有效性
N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15.
8
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.辉瑞-BioNTech 疫苗加强针在以色列预防新冠病毒。
N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15.
9
Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce.在高度接种疫苗的医疗系统工作人员中出现的新冠病毒感染复发现象。
N Engl J Med. 2021 Sep 30;385(14):1330-1332. doi: 10.1056/NEJMc2112981. Epub 2021 Sep 1.
10
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.